MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Huntingtons disease"

  • 2016 International Congress

    A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)

    H.H. Fernandez, S.A. Factor, R.A. Hauser, J. Jimenez-Shahed, W. Ondo, M.S. LeDoux, D. Shprecher, T. Simuni, D. Stamler, K.E. Anderson (Cleveland, OH, USA)

    Objective: To determine the efficacy and safety of deutetrabenazine (DTB) as a treatment for tardive dyskinesia (TD). Background: There is no approved treatment for TD,…
  • 2016 International Congress

    Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

    M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

    Objective: To assess functional connectivity in the premanifest and manifest period of Huntington's disease (HD) by using functional Magnetic Resonance Imaging (fMRI) at high-field (7…
  • 2016 International Congress

    Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease

    L. Brabcová, J. Roth, O. Horácek, M. Kolárová, H. Bozková, J. Rusz, P. Košková, K. Lísalová, F. Jancok, J. Klempír, E. Ruzicka, H. Brozová (Beroun, Czech Republic)

    Objective: To evaluate long-term effects of targeted rehabilitation on postural and gait stability in the early and middle stages of Huntington disease (HD). Background: HD…
  • 2016 International Congress

    A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome

    J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T.K. Murphy, D. Shprecher, D. Stamler (Houston, TX, USA)

    Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…
  • 2016 International Congress

    Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies

    F. Niccolini, G. Pagano, P. Fusar-Poli, A. Wood, L. Mrzljak, C. Sampaio, M. Politis (London, United Kingdom)

    Objective: To systematically examine the evidence of striatal molecular alterations in premanifest and manifest Huntington's disease gene expansion carriers (HDGECs) as measured by Positron emission…
  • 2016 International Congress

    Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

    D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

    Objective: To assess epidemiology and economic burden of falls and fractures among Huntington's disease (HD) patients. Background: The clinical course of HD is characterized by…
  • 2016 International Congress

    Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT

    R. Maciel, D. Maia, C.F. de Lima, F. Cardoso (Belo Horizonte, Brazil)

    Objective: To report the findings of reduced striatal dopamine transporter (DAT) density in patients with Sydenham's chorea (SC) in remission assessed by single-photon emission computed…
  • 2016 International Congress

    Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report

    K. Giehl, K. Reetz, I. Dogan, C. Werner, J.B. Schulz, A. Drzezga, T. van Eimeren (Köln, Germany)

    Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…
  • 2016 International Congress

    Predictors of quality of life in Huntington’s disease. A longitudinal observational study

    A. Brás, F. Júlio, M. Sousa, F. Blanco, C. Januário (Coimbra, Portugal)

    Objective: To analyze predictors and progression of quality of life in patients with Huntington's disease (HD), on a longitudinal assessment over two years. Background: HD…
  • 2016 International Congress

    Juvenile chorea: Diagnostic criterias, prediction of movement disorders

    M.D. Sanoeva, N.A. Mansurova, M. Avezova (Bukhara, Uzbekistan)

    Objective: To determine significant criteria of disease and to predict development of movement disorders depending on severity of disease expression and duration for its promptly…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley